We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-3.89%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.66B
AUM Growth
-$158M
Cap. Flow
-$17.9M
Cap. Flow %
-1.08%
Top 10 Hldgs %
76.19%
Holding
43
New
1
Increased
5
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.4M
2
AZN icon
AstraZeneca
AZN
+$11.7M
3
ALKS icon
Alkermes
ALKS
+$2.9M
4
FOLD
Amicus Therapeutics
FOLD
+$1.14M
5
SAGE
Sage Therapeutics
SAGE
+$799K

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$17.8M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$17.4M
3
ABMD
Abiomed Inc
ABMD
+$11.6M
4
PRTA icon
Prothena Corp
PRTA
+$2.87M

Sector Composition

Rank Sector Weight
1 Healthcare 96.14%
2 Financials 2.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
26
DELISTED
Kezar Life Sciences
KZR
$5.67M 0.34%
65,620
– –
CYTK icon
27
Cytokinetics
CYTK
$10.5B
$4.42M 0.27%
123,686
– –
KLDO
28
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$4.29M 0.26%
786,400
– –
TVTX icon
29
Travere Therapeutics
TVTX
$5.86B
$4.03M 0.24%
166,069
– –
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$3.26M 0.2%
214,700
– –
DNTH icon
31
Dianthus Therapeutics
DNTH
$6.29B
$3.15M 0.19%
27,019
– –
RIGL icon
32
Rigel Pharmaceuticals
RIGL
$782M
$2.37M 0.14%
65,240
– –
ALDX icon
33
Aldeyra Therapeutics
ALDX
$91.7M
$1.41M 0.09%
160,800
– –
TCMD icon
34
Tactile Systems Technology
TCMD
$555M
$1.21M 0.07%
27,100
– –
ATNX
35
DELISTED
Athenex, Inc. Common Stock
ATNX
$958K 0.06%
15,910
– –
ALIM
36
DELISTED
Alimera Sciences
ALIM
$848K 0.05%
200,919
– –
URGN icon
37
UroGen Pharma
URGN
$2.39B
$412K 0.02%
24,500
– –
SYRS
38
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$360K 0.02%
8,060
– –
MRNS
39
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$357K 0.02%
31,330
– –
VIRX
40
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$266K 0.02%
33,212
– –
ACGN
41
DELISTED
Aceragen Inc
ACGN
$79K ﹤0.01%
4,537
– –
NERV icon
42
Minerva Neurosciences
NERV
$187M
$63K ﹤0.01%
4,540
– –
ALXN
43
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-94,850
Closed -$17.4M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q3 2021 Portfolio in Review

As of Q3 2021, Palo Alto Investors held 43 positions worth $1.66B, down 8.7% from $1.81B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Trading was light in Q3 2021: portfolio turnover was 4.7%. Palo Alto Investors opened 1 new position and exited 1, leaving the 43-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q3 2021 buy was AstraZeneca: 100,745 shares worth $12.1M.
  • Palo Alto Investors added most to Dicerna Pharmaceuticals, Inc. in Q3 2021, an estimated $14.4M increase.
  • Palo Alto Investors's biggest Q3 2021 reduction was STAAR Surgical, cutting an estimated $17.8M.
  • Palo Alto Investors fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $17.4M.
  • Palo Alto Investors's ten largest holdings make up 76% of its $1.66B portfolio in Q3 2021.
  • Palo Alto Investors opened 1 new position and closed 1 in Q3 2021.
  • Palo Alto Investors's portfolio value fell 8.7% quarter-over-quarter to $1.66B.

Based on Palo Alto Investors's 13F filing for Q3 2021, filed 15 Nov 2021.